![]() ![]() We expect this trend to have continued in the second quarter of 2023, benefiting the company’s top line. Last quarter, Bio-Rad witnessed a strong rebound in the placement of instruments in China, providing a solid foundation for increased reagent pull-through volumes in the coming quarters. However, manufacturing constraints are expected to have affected the product supply. The year-over-year growth is likely to have been driven by robust demand for diagnostic instruments, primarily within blood typing and diabetes. Clinical DiagnosticsĮxcluding COVID-19-related sales, core Clinical Diagnostics sales are expected to have increased in the second quarter compared to the prior-year period. Per our model, revenues from this segment indicate an improvement of 22.9% year over year to $396.3 million in the second quarter of 2023. On the supply-chain front, Bio-Rad is expected to have made progress in reducing the elevated Life Science backlog position throughout the second quarter. ![]() The overall performance in Russia is likely to have dented the company’s quarterly sales due to the further tightening of sanctions. Geographically, we anticipate the Life Science segment to have posted core organic revenue growth in the Americas and Europe similar to the first quarter. In the first quarter, Bio-Rad experienced softness in smaller biopharma companies and a tough comparison for the process chromatography franchise related to a very large customer order in the first quarter of 2022, which resulted in a year-over-year decline in revenues. Quoteĭespite the sales slowdown in the last quarter, the process chromatography franchise is expected to have witnessed growth, backed by the solid and consistent underlying demand for the business. price-eps-surprise | Bio-Rad Laboratories, Inc. Price and EPS Surpriseīio-Rad Laboratories, Inc. The addition is likely to have expanded Bio-Rad’s oncology assay menu for Droplet Digital PCR, which buoys optimism. This assay kit includes an automated analysis package and enables clinical researchers to assess microsatellite instability status across multiple cancers. On the last earnings call the company highlighted the expected launch of the ddPCR microsatellite instability kit toward the end of the second quarter. During the first quarter months, the demand for the new QX600 Droplet Digital PCR (ddPCR) system and customer acceptance has been remarkable, which we expect to have significantly benefited BIO’s top line in the to-be-reported quarter. Factors at Playīio-Rad’s Life Science segment is likely to have witnessed year-over-year currency-neutral core revenue growth in the second quarter, driven by qPCR products, Western loading and digital PCR. Cancer biomarker studies and copy number variationįor extended product descriptions and detail specification information, please visit ’s look at how things have shaped up before this announcement.Simple workflow with 96-sample throughput.Convenient assay design – standard curves are not required.Flexible assay setup – scalable for high sensitivity or high throughput.Reduced bias from amplification efficiency and PCR inhibitors.Flexible digital PCR chemistry – optimized for TaqMan hydrolysis probe and EvaGreen applications.Winner of the SelectScience Scientists' Choice Awards Best New Life Sciences Product of 2013.Alternatively, amplified products can be extracted from droplets following PCR for downstream applications, such as sequencing or cloning. The PCR-positive and PCR-negative droplets are counted to provide absolute quantification of target DNA in digital form. Up to 96 samples can be processed per run. Droplets are sipped, and the singulator unpacks the emulsified droplets and streams them in single file past a two-color optical detection system in a serial manner. ![]() After PCR on a thermal cycler, droplets from each sample are analyzed individually on the QX200 droplet reader. The QX200 droplet generator partitions the ddPCR reaction mix into 20,000 nanoliter-sized droplets. The new QX200 ddPCR system puts this powerful technology in your hands, ready to unveil new worlds of research at previously unattainable levels. ddPCR addresses the lack of scalable and practical technologies for digital PCR implementation. With unrivaled precision, ddPCR provides absolute quantification of target DNA or RNA molecules without the use of standard curves. Use the QX200 Droplet Digital PCR (ddPCR™) system, the most precise and sensitive PCR solution, for absolute quantification of target DNA molecules.ĭroplet Digital PCR (ddPCR™) is Bio-Rad's unique digital PCR technology. LC-MS innovation: Improve analytical accuracy Which microbioreactor modules are best for you Which solid support is right for your oligo synthesis? 2023 ADLM Annual Scientific Meeting & Clinical Lab Expo. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |